Skye Bioscience
SKYE
65 hedge funds and large institutions have $71.3M invested in Skye Bioscience in 2024 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 27 increasing their positions, 9 reducing their positions, and 13 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 9
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
2% less funds holding
Funds holding: 66 → 65 (-1)
1.72% less ownership
Funds ownership: 84.81% → 83.09% (-1.7%)
29% less capital invested
Capital invested by funds: $101M → $71.3M (-$29.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$3.45M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.94M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$140K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$134K |
| 5 |
BlackRock
New York
|
+$111K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.63M |
| 2 |
AIC
AWM Investment Company
New York
|
-$1.56M |
| 3 |
Millennium Management
New York
|
-$1.54M |
| 4 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$825K |
| 5 |
ACM
Altium Capital Management
New York
|
-$736K |
SKYE Hedge Fund Activity: Q4 2024 in Review
65 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Skye Bioscience (SKYE) for Q4 2024, worth a combined $71.3M — down 29% from $101M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of SKYE and 12 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 27 added.
The largest buyer was Braidwell, opening a new position worth an estimated $3.45M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.63M sold.
- 65 institutional investors held Skye Bioscience (SKYE) as of Q4 2024, down from 66 in Q3 2024.
- Funds reported $71.3M of Skye Bioscience stock for Q4 2024, down 29% quarter-over-quarter.
- 12 funds opened new Skye Bioscience positions in Q4 2024 and 13 closed out, a net change of -1 holder.
- The largest Skye Bioscience buyer in Q4 2024 was Braidwell, an estimated $3.45M added.
- The largest Skye Bioscience seller in Q4 2024 was Point72 Asset Management, an estimated $1.63M sold.
Based on aggregated 13F filings for Q4 2024.